--- title: "DaVita: Competitors & Industry Structure" description: "DaVita compared with companies that share its SEC industry classification: revenue, growth and margins from SEC filings, and how the peer group is chosen." canonical: https://www.getswoopr.com/stocks/companies/davita/competitors/ source: "Swoopr Investment: https://www.getswoopr.com" --- # DaVita: Competitors & Industry Structure ## Direct Answer SEC EDGAR classifies DaVita under SIC code 8090 (Services-Misc Health & Allied Services, NEC). Among Swoopr's S&P 500 Equal Weight companies, 6 others share that classification; by latest reported revenue, DaVita ranks 1 of 7. A filing classification is a starting point: a company's real competitors depend on its segments, which its 10-K describes. ## How Does DaVita Compare With Its Peers? | Company | Revenue (latest FY) | Revenue growth | Operating margin | Net margin | | --- | --- | --- | --- | --- | | **DaVita (DVA)** | $13.6 billion FY2025 | 6.5% | 15.0% | 7.9% | | [agilon health inc. (AGL)](https://www.getswoopr.com/stocks/companies/agilon-health-inc/) | $5.9 billion FY2025 | -2.1% | -7.8% | -6.6% | | [Sotera Health Company (SHC)](https://www.getswoopr.com/stocks/companies/sotera-health-company/) | $1.2 billion FY2025 | 5.7% | n/a | 6.7% | | [Viemed Healthcare Inc. (VMD)](https://www.getswoopr.com/stocks/companies/viemed-healthcare-inc/) | $270 million FY2025 | 20.5% | 8.5% | 5.7% | | [Cryo-Cell International Inc. (CCEL)](https://www.getswoopr.com/stocks/companies/cryo-cell-international-inc/) | $32 million FY2025 | -1.3% | 1.5% | -7.7% | | [Mangoceuticals Inc. (MGRX)](https://www.getswoopr.com/stocks/companies/mangoceuticals-inc/) | $456,021 FY2025 | -26.0% | -3954.3% | -4526.8% | | [BioRestorative Therapies Inc. (BRTX)](https://www.getswoopr.com/stocks/companies/biorestorative-therapies-inc/) | $359,700 FY2025 | -10.3% | -4350.1% | -3959.4% | Revenue growth compares each company's latest fiscal year with the one before. Fiscal years do not always end on the same date, so treat close comparisons with care. ![Bar chart of operating margin for DaVita and 5 peers: DaVita (DVA) 15.0%, agilon health inc. (AGL) -7.8%, Viemed Healthcare Inc. (VMD) 8.5%, Cryo-Cell International Inc. (CCEL) 1.5%, Mangoceuticals Inc. (MGRX) -3954.3%, BioRestorative Therapies Inc. (BRTX) -4350.1%.](https://www.getswoopr.com/images/charts/davita-competitors-peer-margins.webp) *Operating margin of DaVita against companies sharing its SEC industry classification, from the table above. Select the chart to open it full size.* ## How Does DaVita Rank Among All SEC Filers in Its Industry Code? 7 companies with annual reports in Swoopr's SEC dataset share SIC code 8090 (Services-Misc Health & Allied Services, NEC), a wider group than the S&P 500 Equal Weight companies above. Ranks run from 1 (highest) and use each company's latest fiscal year, in U.S. dollars. | Measure | DaVita | Median of filers | Rank | | --- | --- | --- | --- | | Revenue | $13.6 billion | $270 million | 1 of 7 | | Revenue growth | 6.5% | -1.3% | 2 of 7 | | Operating margin | 15.0% | -3.1% | 1 of 6 | | Net margin | 7.9% | -6.6% | 1 of 7 | A SIC code reflects the filer's main business as the SEC records it, so the group mixes companies of very different size; the median is a better guide than the average, and a rank near the top by revenue says nothing about quality. ## Where These Numbers Come From Every figure on this page is a value DaVita reported in its own SEC filings, read from the SEC's XBRL data (accession 0000927066-26-000012 for fiscal year 2025). Ratios are computed from those reported values. Figures were retrieved on October 12, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary. Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation. ## Frequently Asked Questions ### Who are DaVita's competitors? Companies sharing DaVita's SEC classification (SIC code 8090 (Services-Misc Health & Allied Services, NEC)) include agilon health inc. (AGL), Sotera Health Company (SHC), Viemed Healthcare Inc. (VMD), Cryo-Cell International Inc. (CCEL), Mangoceuticals Inc. (MGRX). Its 10-K names the competitors it considers most relevant. ### How does DaVita compare with its peers on margins? DaVita's fiscal 2025 operating margin was 15.0%, against a peer median of -7.8%. ### How are these peers chosen? By the SEC Standard Industrial Classification code each company files under, within Swoopr's S&P 500 Equal Weight company set, falling back to the two-digit major group when fewer than two companies share the exact code. Classification codes are broad, so read the peer list as a screen, not a verdict. ### How does DaVita rank among all companies in its SEC industry? Among 7 SEC filers under SIC code 8090, DaVita ranks 1 by latest revenue, and 1 of 6 by operating margin (15.0% against a median of -3.1%). ## References - [SEC EDGAR: DAVITA INC. Form 10-K filed February 11, 2026](https://www.sec.gov/Archives/edgar/data/927066/000092706626000012/dva-20251231.htm) - [SEC EDGAR: DAVITA INC. annual and quarterly filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=927066&type=10-K) - [SEC: EDGAR application programming interfaces (XBRL frames and submissions data)](https://www.sec.gov/search-filings/edgar-application-programming-interfaces) ## Related Pages - [DaVita company dossier](https://www.getswoopr.com/stocks/companies/davita/) - [DaVita financial metrics](https://www.getswoopr.com/stocks/companies/davita/metrics/) - [DaVita financial risk indicators](https://www.getswoopr.com/stocks/companies/davita/risks/) - [DaVita peer comparison](https://www.getswoopr.com/stocks/companies/davita/competitors/) - [DaVita business model and revenue mix](https://www.getswoopr.com/stocks/companies/davita/business-model/) - [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/) **[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)** Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).